Skip to main content
VALIRX PLC logo

VALIRX PLC — Investor Relations & Filings

Ticker · VAL ISIN · GB00BLH13C52 LEI · 213800VQKB9SJCQDET40 IL Professional, scientific and technical activities
Open in API
Filings indexed 574 across all filing types
Latest filing 2017-10-02 Regulatory Filings
Country GB United Kingdom
Listing IL VAL

About VALIRX PLC

https://www.valirx.com/

ValiRx PLC is a life science company that accelerates the development of therapeutics and diagnostics, with a primary focus on oncology and women's health. The company's business model centers on identifying and progressing promising early-stage scientific discoveries through pre-clinical and clinical development. ValiRx provides scientific, financial, and commercial expertise to translate novel research into clinically validated treatments, aiming to improve patient outcomes in its target therapeutic areas.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Regulatory Filings Classification · 1% confidence The document is explicitly labeled with "RNS Number : 1466S" and concludes with "This information is provided by RNS The company news service from the London Stock Exchange". The content announces the 'Total Voting Rights' of the company, which is a mandatory regulatory disclosure in the UK, often disseminated via the Regulatory News Service (RNS). While it relates to share capital (which could suggest SHA), the primary function and format are that of a general regulatory announcement disseminated through the official channel, making RNS the most appropriate classification, especially since it corrects a previous RNS notification.
2017-10-02 English
ValiSeek Clinical Development Update
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 0182S' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange END'. This strongly indicates a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details a 'VALISEEK CLINICAL DEVELOPMENT UPDATE' regarding a Phase II clinical trial for a drug (VAL401), providing specific scientific results (pharmacokinetic measurements) and commercial updates. This is a substantive update on clinical progress, not just a notice that a report is attached (which would suggest RPA). Since it is a specific regulatory announcement that doesn't fit perfectly into categories like ER, IR, or LTR, the most appropriate general regulatory filing category is RNS.
2017-09-28 English
Holding(s) in Company
Major Shareholding Notification Classification · 1% confidence The document is identified by the header 'RNS Number : 0040S' and contains the standard format 'TR-1: Standard form for notification of major holdings'. This form is used to report changes in significant share ownership, which directly corresponds to the definition of Major Shareholding Notification. The filing explicitly details the percentage of voting rights held (3.48%) and the date the threshold was crossed. This aligns perfectly with the 'Major Shareholding Notification' category (MRQ). Although it is an RNS filing, MRQ is the more specific and appropriate classification.
2017-09-27 English
Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'HALF YEARLY REPORT FOR THE PERIOD ENDED 30 JUNE 2017' and contains comprehensive financial statements, including a consolidated statement of comprehensive income and a statement of changes in shareholders' equity. It provides detailed operational and financial highlights, a Chairman's statement, and financial data for the interim period. It is not a mere announcement or certification, but the full interim report itself. H1 2017
2017-09-26 English
VAL201 update
Legal Proceedings Report Classification · 1% confidence The document is very short (3005 characters) and is explicitly identified as an 'RNS Number : 3340R'. It addresses market speculation regarding the status of a clinical trial ('VAL201 update') and confirms the trial is ongoing, stating it looks forward to updating the market 'in due course'. This structure—a brief announcement addressing a specific market query or providing a minor update, issued via the RNS system—fits the definition of a general regulatory announcement that doesn't fit a more specific category like ER, 10-K, or DIV. According to Rule 2, since it is short and provides an update rather than the full report, it is best classified as a general regulatory filing, which corresponds to the RNS code.
2017-09-20 English
Issue of Equity
Share Issue/Capital Change Classification · 1% confidence The document is identified by the header 'RNS Number : 0927R' and contains an announcement titled 'Issue of Equity'. It details a placing to raise £0.5 million through the issue of 50,000,000 new ordinary shares. This is a specific corporate action related to capital structure changes (issuing new shares for fundraising). This aligns directly with the definition of 'Share Issue/Capital Change' (SHA). Although it is distributed via RNS, the content is specific enough to warrant the SHA classification over the general RNS fallback.
2017-09-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.